IRIDEX (IRIX) Expected to Announce Earnings on Monday

IRIDEX (NASDAQ:IRIX) is expected to release its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect IRIDEX to post earnings of ($0.07) per share and revenue of $11.91 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 5:00 PM ET.

IRIDEX (NASDAQ:IRIX) last released its quarterly earnings data on Thursday, March 26th. The medical equipment provider reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.01. The firm had revenue of $14.72 million for the quarter, compared to the consensus estimate of $14.74 million. IRIDEX had a negative net margin of 8.42% and a negative return on equity of 1,204.74%.

IRIDEX Stock Performance

IRIX stock traded up $0.06 during trading on Monday, reaching $1.09. 25,578 shares of the company were exchanged, compared to its average volume of 221,361. IRIDEX has a 52-week low of $0.87 and a 52-week high of $1.65. The company has a market cap of $18.87 million, a P/E ratio of -4.17 and a beta of 0.64. The stock’s 50 day moving average price is $1.20 and its 200 day moving average price is $1.17.

Analyst Ratings Changes

IRIX has been the topic of several recent research reports. Alliance Global Partners initiated coverage on shares of IRIDEX in a report on Thursday, February 5th. They issued a “buy” rating on the stock. iA Financial set a $3.00 price target on shares of IRIDEX in a report on Thursday, February 5th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $3.00.

Hedge Funds Weigh In On IRIDEX

Several institutional investors and hedge funds have recently modified their holdings of IRIX. Jane Street Group LLC lifted its stake in shares of IRIDEX by 93.9% during the fourth quarter. Jane Street Group LLC now owns 31,758 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 15,377 shares during the period. Susquehanna International Group LLP lifted its stake in shares of IRIDEX by 46.2% during the third quarter. Susquehanna International Group LLP now owns 56,470 shares of the medical equipment provider’s stock valued at $65,000 after buying an additional 17,834 shares during the period. Apexium Financial LP lifted its stake in shares of IRIDEX by 53.0% during the third quarter. Apexium Financial LP now owns 100,529 shares of the medical equipment provider’s stock valued at $116,000 after buying an additional 34,834 shares during the period. Finally, Citadel Advisors LLC lifted its stake in shares of IRIDEX by 62.7% during the third quarter. Citadel Advisors LLC now owns 109,473 shares of the medical equipment provider’s stock valued at $126,000 after buying an additional 42,202 shares during the period. Hedge funds and other institutional investors own 20.10% of the company’s stock.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) is a medical technology company specializing in the development, manufacturing and commercialization of innovative ophthalmic laser and imaging systems. The company’s offerings focus on energy-based therapies designed to treat retinal vascular disorders, glaucoma and other ocular conditions. IRIDEX’s portfolio includes laser photocoagulation platforms, micro-pulse laser technology, and related consumable devices for use by ophthalmologists and retina specialists.

The company’s flagship products include the Cyclo G6 Glaucoma Laser System, which delivers precise, controlled micro-pulse laser therapy for patients with refractory glaucoma, and the IQ 532 Retina Laser System, designed to support minimally invasive laser treatments for diabetic retinopathy and age-related macular degeneration.